The IOZK is a translational center and develops immuno-oncological procedures on the basis of new scientific findings.
These are combined in the best possible way for each individual patient. For this reason, no randomized clinical trials are conducted at the IOZK. These require the same treatment protocol for all patients in the experimental group and a comparison group that does not receive any treatment. In science, new research methods are being developed and discussed that are better suited to investigating the effectiveness of a highly individualized therapy. It is very important to us to contribute to scientific progress and the development of modern immunotherapy against tumor diseases.
Here we provide scientific papers published by IOZK employees.
IOZK article in the journal for orthomolecular medicine, special issue: Oncology
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines
Report by Prof. Dr. Schirrmacher in the International Journal of Oncology on the findings of tumor-reactive T-cell memory in the bone marrow
Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance
Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma
Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients
ZEIT supplement: Living with cancer with an article about the IOZK and the IOZK immunotherapy
Brain Tumor Immunotherapy: What have We Learned so Far?
IOZK case study on the long-term survival of a patient with breast cancer
Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
Article by Prof. Dr. Schirrmacher in the Viennese medical weekly "Skriptum"
Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?
Prof. Dr. Schirrmacher publishes e-book: Harnessing Oncolytic Virus-mediated Antitumor Immunity
IOZK case study on the successful treatment of metastatic prostate cancer
Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
Strong T‑cell costimulation can reactivate tumor antigen‑specific T cells in late‑stage metastasized colorectal carcinoma patients: results from a phase Ⅰ clinical study
Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies
Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells
Wilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies